Skip to main content
Home
Issues
2023
June 2023 - Vol 16 No 1
2022
December - Vol 15 No 4
September - Vol 15 No 3
June - Vol 15 No 2
March - Vol 15 No 1 - Online Only
Issue Archive
Special Issues
September 2023 Vol 16, Payers' Guide to FDA Updates
Supplements
Special Issue Archive
Topics
Conference Correspondent
Web Exclusives
Web Exclusive Topics
All Web Exclusives
Select Drug Profiles
FDA Approvals
In the News
Press Releases
Videos
Interview with the Innovators
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Reprints
Subscribe
Home
Issues
2023
June 2023 - Vol 16 No 1
2022
December - Vol 15 No 4
September - Vol 15 No 3
June - Vol 15 No 2
March - Vol 15 No 1 - Online Only
Issue Archive
Special Issues
September 2023 Vol 16, Payers' Guide to FDA Updates
Supplements
Special Issue Archive
Topics
Conference Correspondent
Web Exclusives
Web Exclusive Topics
All Web Exclusives
Select Drug Profiles
FDA Approvals
In the News
Press Releases
Videos
Interview with the Innovators
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Reprints
Lung Cancer
Lung Cancer
A Look at PD-1 and PD-L1 Inhibitors
Edward Garon, MD
Play Video
Lung Cancer
Adjuvant Osimertinib a Practice-Changing Treatment in Early-Stage NSCLC with EGFR Mutation
Wayne Kuznar
Wayne Kuznar
Play Video
Lung Cancer
Afatinib Boosts PFS in EGFR Mutation–Positive Lung Cancer
Wayne Kuznar
Play Video
Lung Cancer
Afatinib Doubles Progression-Free Survival Compared with Chemotherapy in Patients with Lung Cancer
Wayne Kuznar
Play Video
Lung Cancer
Alectinib New Standard of Care for ALK-Positive Non–Small-Cell Lung Cancer
Phoebe Starr
Play Video
Lung Cancer
Alectinib Potential First-Line Treatment for NSCLC Associated with ALK Mutation
Wayne Kuznar
Play Video
Lung Cancer
ALK Gene Rearrangement and PD-L1 Expression
Edward Garon, MD
Play Video
Lung Cancer
,
Select Drug Profiles
,
Payers' Guide
Alunbrig (Brigatinib) Approved for Metastatic NSCLC with ALK Mutation
Lisa A. Raedler, PhD, RPh
Play Video
Conference Highlights ASCO
,
Lung Cancer
Atezolizumab Extends Disease-Free Survival in PD-L1−Positive Early-Stage NSCLC
Phoebe Starr
Phoebe Starr
Play Video
Lung Cancer
BLU-667, Selective RET Inhibitor, Demonstrates Antitumor Activity in NSCLC with RET Fusion
Wayne Kuznar
Wayne Kuznar
Play Video
1
2
3
4
Page 1 of 5
Results 1 - 10 of 44